Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SAGA PLC Share Issue/Capital Change 2018

Jul 5, 2018

4914_rns_2018-07-05_04d4b919-be70-4391-a6bf-459eed0f0503.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7435T

SAGA PLC

05 July 2018

5 July 2018

Saga plc

("Saga" or the "Company")

Issue of equity

Saga plc has issued 1,707,909 new ordinary shares of 1 penny each in the Company for transfer into an employee benefit trust to satisfy employee incentive arrangements. The newly issued shares will rank pari passu with existing Saga shares.

Applications have been made to the Financial Conduct Authority for the listing of the shares on the Official List and to the London Stock Exchange for admission of the shares to trading on the Main Market. The new shares are expected to be admitted to trading at 8 a.m. on 10 July 2018.

Following this issue, the Company's total issued share capital comprises 1,122,003,328 ordinary shares of 1 penny each, of which zero shares are held in treasury. Therefore, the total number of voting rights in Saga plc is 1,122,003,328; this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Saga under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries

Saga plc

Enbrook Park

Sandgate

Folkestone

Kent

CT20 3SE
Vicki Haynes

Company Secretary

01303 771 199

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

IOESSDFSIFASELW